

Enantioselective Synthesis of Allylboronates and Allylic Alcohols by Copper-Catalyzed 1,6-Boration**

Yunfei Luo, Iain D. Roy, Amaël G. E. Madec, and Hon Wai Lam*

Abstract: Chiral secondary allylboronates are obtained in high enantioselectivities and 1,6:1,4 ratios by the copper-catalyzed 1,6-boration of electron-deficient dienes with bis(pinacolato)-diboron ($B_2(\text{pin})_2$). The reactions proceed efficiently using catalyst loadings as low as 0.0049 mol %. The allylboronates may be oxidized to the allylic alcohols, and can be used in stereoselective aldehyde allylboration. This process was applied to a concise synthesis of atorvastatin, in which the key 1,6-boration was performed using only a 0.02 mol % catalyst loading.

Enantioselective transition-metal-catalyzed reactions have transformed the way in which enantiomerically enriched chiral compounds can be prepared. However, the majority of industrial-scale catalytic asymmetric processes developed to date employ precious second- or third-row transition metals that are costly and limited in availability.^[1] Moreover, the chiral ligands employed in these reactions are often expensive. Therefore, new enantioselective reactions that are catalyzed by earth-abundant metals, and that proceed efficiently at very low catalyst loadings to minimize the quantity of chiral ligand employed, are in high demand.

Given the ability of electron-deficient dienes to serve as effective substrates for various catalytic asymmetric 1,6-addition reactions,^[2,3] we became interested in the enantioselective 1,6-boration of $\alpha,\beta,\gamma,\delta$ -unsaturated carbonyl compounds as a potential method to prepare functionalized chiral allylboronates^[4] and allylic secondary alcohols,^[5] which are versatile building blocks for synthesis. Although enantioselective 1,4-borations of electron-deficient alkenes are well-

established using chiral catalysts based upon copper,^[6–8] other metals,^[9] or by using organocatalysts,^[10] the enantioselective 1,6-boration of electron-deficient dienes is not well-developed. Progress has been made in related processes, such as enantioselective copper-catalyzed monoboration^[4b] and platinum-catalyzed 1,4-diboration of 1,3-dienes.^[11] Kobayashi and co-workers also recently reported four examples of enantioselective Cu^{II} -catalyzed 1,6-borations of $\alpha,\beta,\gamma,\delta$ -unsaturated cyclic ketones with 33–89 % *ee*, using a 5 mol % catalyst loading.^[12] However, these substrates were disubstituted at the β -position, and acyclic $\alpha,\beta,\gamma,\delta$ -unsaturated carbonyls lacking an additional group at the β -carbon underwent exclusive 1,4-boration.


Herein, we describe highly enantioselective copper-catalyzed 1,6-borations of acyclic $\alpha,\beta,\gamma,\delta$ -unsaturated esters and ketones. High selectivities for 1,6-boration over 1,4-boration are achieved without a “blocking” substituent at the β -carbon. Furthermore, the chiral copper complex employed exhibits high stability, allowing the reactions to proceed effectively at catalyst loadings as low as 0.0049 mol %. Application of this method to the synthesis of the cholesterol-lowering drug atorvastatin is also described.

This study began with a search for an effective method for the enantioselective copper-catalyzed 1,6-addition of bis(pinacolato)diboron (**1**, 1.2 equiv) to benzyl sorbate (**2a**) (Scheme 1; see the Supporting Information for full details). The best results were obtained using $[\text{CuF}(\text{PPh}_3)_3 \cdot 2\text{MeOH}]$ and the Josiphos ligand **L1**^[6c,d,8c,f] in THF at room temperature, in the presence of *i*PrOH (2.0 equiv) as a protic additive.^[6c,8f] The 1,6-boration of **2a** proceeded smoothly on a 0.50 mmol scale using only 0.20 mol % of the copper complex $[\text{CuF}(\text{PPh}_3)_3 \cdot 2\text{MeOH}/\text{L1}]$ (Scheme 1). After the reaction was complete, filtration of the mixture through a short plug of silica using EtOAc as the eluent and removal of the solvent provided the *E*-allylboronate **3a**, accompanied by HOB(pin). Oxidation of this mixture with $\text{NaBO}_3 \cdot 4\text{H}_2\text{O}$ ^[12] then gave the allylic alcohol **4a** in 91 % yield of isolated product over the two steps and in 95 % *ee*.^[13] Alternatively, pure allylboronate **3a** was isolated in 80 % yield and 96 % *ee* by using 5 % Et_2O /hexane in the filtration of the 1,6-boration reaction mixture.^[14] A range of other $\alpha,\beta,\gamma,\delta$ -unsaturated benzyl esters also underwent enantioselective 1,6-boration–oxidation to provide allylic alcohols **4a–4f** in 70–92 % yield, high regioselectivities (> 19:1 ratio of 1,6:1,4-addition) and high enantioselectivities (95–96 % *ee*). Along with benzyl sorbate (**2a**), substrates containing other linear alkyl groups at the δ -position were effective (**4b** and **4c**). The process is compatible with nitrogen-containing substituents (**4d** and **4h**), an alkyl chloride (**4e**), and silyl ethers (**4f** and **4g**). Substrates containing ethyl esters (**4g** and **4h**) or *tert*-butyl

[*] Dr. Y. Luo, I. D. Roy, A. G. E. Madec, Prof. H. W. Lam
EaStCHEM, School of Chemistry, University of Edinburgh
Joseph Black Building, The King's Buildings
West Mains Road, Edinburgh EH9 3JJ (UK)
Dr. Y. Luo, A. G. E. Madec, Prof. H. W. Lam
School of Chemistry, University of Nottingham
University Park, Nottingham, NG7 2RD (UK)
E-mail: hon.lam@nottingham.ac.uk
Homepage: <http://www.nottingham.ac.uk/~pczh1>

[**] We thank the ERC (Starting Grant No. 258580), the EPSRC (Leadership Fellowship to H.W.L.), Pfizer, AstraZeneca, and the University of Edinburgh for support. We thank Xiaoming Yang of Shanghai Chiral Chemistry Co., Ltd. for providing starting materials and NMR data for atorvastatin (**13**). We are grateful to Dr. Gary S. Nichol (University of Edinburgh) for X-ray crystallography, and the EPSRC National Mass Spectrometry Facility for high-resolution mass spectra. We thank Dr. Ai-Lan Lee at Heriot-Watt University for the use of a polarimeter.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201310380>.




Scheme 1. Scope of enantioselective 1,6-boration–oxidation. Reactions were conducted with 0.50 mmol of **2**. Cited yields are of isolated material. Enantiomeric excesses were determined by HPLC analysis on a chiral stationary phase. [a] Pure allylboronate **3a** ($R^1 = \text{Me}$, $R^2 = \text{OBn}$) was isolated in 80% yield and 96% ee without performing the oxidation. [b] Enantiomeric excess determined on the corresponding benzoate ester. [c] Oxidation was performed using 5.0 equiv of $\text{NaBO}_3 \cdot 4\text{H}_2\text{O}$. [d] Isolated as a 12:1 inseparable mixture of **4j** and the *E*-conjugated enone. [e] Isolated as a 15:1 inseparable mixture of **4l** and the *E*-conjugated enone.

esters (**4i**) were also tolerated. However, a substrate containing a phenyl group at the δ -position provided a complex mixture of unidentified products. The process is not limited to esters as the activating group; $\alpha,\beta,\gamma,\delta$ -unsaturated aryl and alkyl ketones were also effective (**4j–4m**).


The selectivity for 1,6-boration over 1,4-boration is sensitive to steric effects, as shown by the boration–oxidation of **2n**, which contains a δ -cyclopropyl group. This reaction gave the 1,4-adduct **5a** as the major product in 49% yield and 77% ee, while the 1,6-adduct **4n** was isolated in 25% yield and 87% ee [Eq. (1)]. Increasing the size of the δ -substituent further led to exclusive 1,4-boration, as shown by the cyclohexyl-substituted substrate **2o**, which gave the β -hydroxyster **5b** only, in 89% yield and 87% ee [Eq. (2)].

The sense of enantioinduction in these reactions was determined by X-ray crystallography of potassium allyltrifluoroborate **6**, which was obtained by 1,6-boration of **2i**




Scheme 2. Conversion of **2i** into the allyltrifluoroborate **6**.

Next, larger scale 1,6-borations were conducted to assess whether the catalyst loading could be decreased.^[17] A 40.4 mmol scale 1,6-boration of **2a** with 1.06 equiv of $\text{B}_2(\text{pin})_2$ (**1**), 0.0049 mol % of $\text{CuF}(\text{PPh}_3)_3 \cdot 2\text{MeOH}$ and 0.0074 mol % of **L1** was complete in 30 h, providing **3a** as an 11:1 mixture of 1,6:1,4-boration isomers (Scheme 3). Oxidation of **3a** then gave **4a** in 80% yield and 95% ee over the two steps. Notably, in this experiment, only 1.9 mg of the chiral ligand **L1** was required to prepare 7.10 g of **4a**.^[17]



Scheme 3. Larger scale 1,6-boration-oxidation of **2a**.

Along with oxidation to allylic alcohols, the allylboronates resulting from 1,6-boration can be employed in stereoselective carbonyl allylboration. For example, treatment of **3a** with benzaldehyde in the presence of $\text{BF}_3 \cdot \text{OEt}_2$ provided homoallylic alcohol **7** in 77% yield as a 23:1 inseparable mixture of *E/Z* isomers, and in 93% ee for the *E*-isomer [Eq. (3)].^[18]



As a further demonstration of its utility, the enantioselective 1,6-boration was applied in a concise synthesis of atorvastatin (**13**), a well-known inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase and the active ingredient in Lipitor, currently the best-selling pharmaceutical in history.^[19–21] The synthesis began with the preparation of diene **8**.^[22] Enantioselective 1,6-boration–oxidation of geometrically pure **8** (obtained in 39% overall yield from commercial starting materials) on a 0.40 mol scale gave the allylic alcohol **9** in 87% yield and 95% *ee* (Scheme 4, top). However, multiple recrystallizations were required to obtain **8** in geometrically pure form, and for reasons of practicality as well as overall yield, it was preferable to use a 16:1 *E:Z* mixture of **8** (obtained in 60% overall yield from commercial starting materials) in the synthesis of atorvastatin (Scheme 4, bottom).^[22]

Enantioselective 1,6-boration of this 16:1 *E:Z* mixture of **8** on a 7.40 mmol scale proceeded smoothly using only 0.02 mol% of the Cu^I-Josiphos complex, and oxidation of the resulting allylboronate with NaBO₃·4H₂O provided the allylic alcohol **9** in 84% *ee* (Scheme 4, bottom). The lower enantioselectivity of this reaction is due to the presence (ca. 6%) of the minor 2*E*,4*Z*-isomer of diene **8**.^[23] Without purification, **9** was isomerized to the conjugated ester **10** with catalytic DBU in MeCN at room temperature. The crude α,β-unsaturated ester **10** was then reacted with benzaldehyde and KO^tBu according to the method of Evans and Gauchet-Prunet,^[24] which gave the benzylidene acetal-protected *syn*-1,3-diol **11** with high diastereoselectivity (>19:1 d.r.).^[21c]

Recrystallization of **11** from *i*PrOH/hexane led to selective crystallization of the racemate, which enabled isolation of an enantioenriched sample of **11** (>99% *ee*) in 34% yield over the four steps from **8** after concentration of the mother liquor. Deprotection of the acetal of **11** with HCl was followed by basic hydrolysis of the ester with NaOH to give the sodium salt **12** of atorvastatin (**13**) in 89% yield, which was converted into atorvastatin (**13**) itself in 94% yield by acidification.

In conclusion, we have reported highly enantioselective copper-catalyzed 1,6-borations of α,β,γ,δ-unsaturated carbonyl compounds with bis(pinacolato)diboron (**1**). For the first time, high selectivities for 1,6-boration over 1,4-boration are achieved without a “blocking” substituent at the β-carbon. The reactions proceed at ambient temperature and are promoted by a Cu^I-Josiphos complex at catalyst loadings as low as 0.0049 mol% to provide chiral allylboronates on the way to chiral secondary allylic alcohols. Application of this process on a 40.4 mmol scale has been demonstrated. The allylboronates may also be employed in highly stereoselective allylboration of aldehydes. Finally, the utility of this method was demonstrated by a concise synthesis of atorvastatin (**13**), the well-known cholesterol-lowering drug. Efforts to understand the origin of the selectivity for 1,6-boration over 1,4-boration, which is currently unclear, along with the development of other catalytic enantioselective 1,6-additions, are topics for future study in our laboratory.


Received: November 29, 2013

Revised: February 3, 2014


Published online: March 12, 2014

Keywords: 1,6-addition · asymmetric catalysis · boron · copper · enantioselectivity

1,6-Boration on a 0.40 mmol scale:




1,6-Boration on a 7.40 mmol scale:



Scheme 4. Enantioselective synthesis of atorvastatin (**13**).

- [1] *Asymmetric Catalysis On Industrial Scale: Challenges, Approaches, And Solutions*, 2nd ed. (Eds.: H.-U. Blaser, H.-J. Federsel), Wiley-VCH, Weinheim, **2010**.
- [2] Metal-catalyzed enantioselective 1,6-additions: a) E. Fillion, A. Wilsily, E. T. Liao, *Tetrahedron: Asymmetry* **2006**, *17*, 2957–2959; b) T. den Hartog, S. R. Harutyunyan, D. Font, A. J. Minnaard, B. L. Feringa, *Angew. Chem.* **2008**, *120*, 404–407; *Angew. Chem. Int. Ed.* **2008**, *47*, 398–401; c) H. Hénon, M. Mauduit, A. Alexakis, *Angew. Chem.* **2008**, *120*, 9262–9264; *Angew. Chem. Int. Ed.* **2008**, *47*, 9122–9124; d) K.-s. Lee, A. H. Hoveyda, *J. Am. Chem. Soc.* **2010**, *132*, 2898–2900; e) K.-s. Lee, H. Wu, F. Haeffner, A. H. Hoveyda, *Organometallics* **2012**, *31*, 7823–7826; f) T. Hayashi, S. Yamamoto, N. Tokunaga, *Angew. Chem.* **2005**, *117*, 4296–4299; *Angew. Chem. Int. Ed.* **2005**, *44*, 4224–4227; g) T. Nishimura, Y. Yasuhara, T. Sawano, T. Hayashi, *J. Am. Chem. Soc.* **2010**, *132*, 7872–7873; h) T. Nishimura, A. Noishiki, T. Hayashi, *Chem. Commun.* **2012**, *48*, 973–975; i) T. Sawano, A. Ashouri, T. Nishimura, T. Hayashi, *J. Am. Chem. Soc.* **2012**, *134*, 18936–18939; j) T. Kitanosono, P. Xu, S. Kobayashi, *Chem. Commun.* **2013**, *49*, 8184–8186; k) J. Lu, J. Ye, W.-L. Duan, *Chem. Commun.* **2014**, *50*, 698–700.
- [3] Organocatalytic enantioselective 1,6-additions: a) L. Bernardi, J. López-Cantarero, B. Niess, K. A. Jørgensen, *J. Am. Chem. Soc.* **2007**, *129*, 5772–5778; b) J. J. Murphy, A. Quintard, P. McArdle, A. Alexakis, J. C. Stephens, *Angew. Chem.* **2011**, *123*, 5201–5204; *Angew. Chem. Int. Ed.* **2011**, *50*, 5095–5098; c) X. Tian, Y. Liu, P. Melchiorre, *Angew. Chem.* **2012**, *124*, 6545–6548; *Angew. Chem. Int. Ed.* **2012**, *51*, 6439–6442; d) D. Uruguchi, K. Yoshioka, Y. Ueki, T. Ooi, *J. Am. Chem. Soc.* **2012**, *134*, 19370–19373; e) L. Dell'Amico, L. Albrecht, T. Naicker, P. H. Poulsen, K. A. Jørgensen, *J. Am. Chem. Soc.* **2013**, *135*, 8063–8070; f) M. Silvi, I. Chatterjee, Y. Liu, P. Melchiorre, *Angew. Chem.* **2013**, *125*, 10980–10983; *Angew. Chem. Int. Ed.* **2013**, *52*, 10780–10783.
- [4] For selected examples of the preparation of enantiomerically enriched chiral allylboron compounds, see: a) J. Pietruszka, N. Schöne, *Angew. Chem.* **2003**, *115*, 5796–5799; *Angew. Chem. Int. Ed.* **2003**, *42*, 5638–5641; b) H. Ito, C. Kawakami, M. Sawamura, *J. Am. Chem. Soc.* **2005**, *127*, 16034–16035; c) F. Peng, D. G. Hall, *Tetrahedron Lett.* **2007**, *48*, 3305–3309; d) L. Carosi, D. G. Hall, *Angew. Chem.* **2007**, *119*, 6017–6019; *Angew. Chem. Int. Ed.* **2007**, *46*, 5913–5915; e) H. Ito, S. Ito, Y. Sasaki, K. Matsuura, M. Sawamura, *J. Am. Chem. Soc.* **2007**, *129*, 14856–14857; f) H. Ito, T. Okura, K. Matsuura, M. Sawamura, *Angew. Chem.* **2010**, *122*, 570–573; *Angew. Chem. Int. Ed.* **2010**, *49*, 560–563; g) H. Ito, S. Kunii, M. Sawamura, *Nat. Chem.* **2010**, *2*, 972–976; h) Y. Sasaki, C. Zhong, M. Sawamura, H. Ito, *J. Am. Chem. Soc.* **2010**, *132*, 1226–1227; i) M. Althaus, A. Mahmood, J. R. Suárez, S. P. Thomas, V. K. Aggarwal, *J. Am. Chem. Soc.* **2010**, *132*, 4025–4028; j) M. Chen, D. H. Ess, W. R. Roush, *J. Am. Chem. Soc.* **2010**, *132*, 7881–7883; k) J. C. H. Lee, R. McDonald, D. G. Hall, *Nat. Chem.* **2011**, *3*, 894–899; l) M. Chen, W. R. Roush, *J. Am. Chem. Soc.* **2011**, *133*, 5744–5747; m) L. T. Kliman, S. N. Mlynarski, G. E. Ferris, J. P. Morken, *Angew. Chem.* **2012**, *124*, 536–539; *Angew. Chem. Int. Ed.* **2012**, *51*, 521–524; n) A. P. Pulis, V. K. Aggarwal, *J. Am. Chem. Soc.* **2012**, *134*, 7570–7574; o) G. E. Ferris, K. Hong, I. A. Roundtree, J. P. Morken, *J. Am. Chem. Soc.* **2013**, *135*, 2501–2504.
- [5] A. Lumbroso, M. L. Cooke, B. Breit, *Angew. Chem.* **2013**, *125*, 1942–1986; *Angew. Chem. Int. Ed.* **2013**, *52*, 1890–1932.
- [6] Seminal references: a) K. Takahashi, T. Ishiyama, N. Miyaura, *Chem. Lett.* **2000**, 982–983; b) H. Ito, H. Yamanaka, J.-i. Tateiwa, A. Hosomi, *Tetrahedron Lett.* **2000**, *41*, 6821–6825; c) S. Mun, J.-E. Lee, J. Yun, *Org. Lett.* **2006**, *8*, 4887–4889; d) J.-E. Lee, J. Yun, *Angew. Chem.* **2008**, *120*, 151–153; *Angew. Chem. Int. Ed.* **2008**, *47*, 145–147; e) V. Lillo, A. Prieto, A. Bonet, M. M. Díaz-Requejo, J. s. Ramírez, P. J. Pérez, E. Fernández, *Organometallics* **2008**, *28*, 659–662.
- [7] Reviews: a) E. Hartmann, D. J. Vyas, M. Oestreich, *Chem. Commun.* **2011**, *47*, 7917–7932; b) A. D. J. Calow, A. Whiting, *Org. Biomol. Chem.* **2012**, *10*, 5485–5497.
- [8] For selected recent examples, see Ref. [4k] and: a) J. M. O'Brien, K.-s. Lee, A. H. Hoveyda, *J. Am. Chem. Soc.* **2010**, *132*, 10630–10633; b) A. L. Moure, R. Gomez Arrayas, J. C. Carretero, *Chem. Commun.* **2011**, *47*, 6701–6703; c) E. Hartmann, M. Oestreich, *Org. Lett.* **2012**, *14*, 2406–2409; d) L. Zhao, Y. Ma, W. Duan, F. He, J. Chen, C. Song, *Org. Lett.* **2012**, *14*, 5780–5783; e) C. Sole, A. Bonet, A. H. M. de Vries, J. G. de Vries, L. Lefort, H. Gulyás, E. Fernández, *Organometallics* **2012**, *31*, 7855–7861; f) A. R. Burns, J. S. Gonzalez, H. W. Lam, *Angew. Chem.* **2012**, *124*, 10985–10989; *Angew. Chem. Int. Ed.* **2012**, *51*, 10827–10831; g) A. D. J. Calow, A. S. Batsanov, E. Fernández, C. Solé, A. Whiting, *Chem. Commun.* **2012**, *48*, 11401–11403; h) S. Kobayashi, P. Xu, T. Endo, M. Ueno, T. Kitanosono, *Angew. Chem.* **2012**, *124*, 12935–12938; *Angew. Chem. Int. Ed.* **2012**, *51*, 12763–12766.
- [9] a) T. Shiomi, T. Adachi, K. Toribatake, L. Zhou, H. Nishiyama, *Chem. Commun.* **2009**, 5987–5989; b) V. Lillo, M. J. Geier, S. A. Westcott, E. Fernández, *Org. Biomol. Chem.* **2009**, *7*, 4674–4676; c) K. Toribatake, L. Zhou, A. Tsuruta, H. Nishiyama, *Tetrahedron* **2013**, *69*, 3551–3560.
- [10] a) A. Bonet, H. Gulyás, E. Fernández, *Angew. Chem.* **2010**, *122*, 5256–5260; *Angew. Chem. Int. Ed.* **2010**, *49*, 5130–5134; b) I. Ibrahim, P. Breistein, A. Cordova, *Chem. Eur. J.* **2012**, *18*, 5175–5179; c) H. Wu, S. Radomkit, J. M. O'Brien, A. H. Hoveyda, *J. Am. Chem. Soc.* **2012**, *134*, 8277–8285.
- [11] a) H. E. Burks, L. T. Kliman, J. P. Morken, *J. Am. Chem. Soc.* **2009**, *131*, 9134–9135; b) C. H. Schuster, B. Li, J. P. Morken, *Angew. Chem.* **2011**, *123*, 8052–8055; *Angew. Chem. Int. Ed.* **2011**, *50*, 7906–7909; c) K. Hong, J. P. Morken, *J. Org. Chem.* **2011**, *76*, 9102–9108.
- [12] C. N. Farthing, S. P. Marsden, *Tetrahedron Lett.* **2000**, *41*, 4235–4238.
- [13] The absolute configurations of the products of this study were assigned by analogy with the allyltrifluoroborate **6**, which was determined by X-ray crystallography (see the Supporting Information).
- [14] The lower yield of **3a** compared with that of **4a** obtained in the two-step procedure is due to decomposition of **3a** on silica during the longer duration of the filtration.
- [15] A. J. J. Lennox, G. C. Lloyd-Jones, *Angew. Chem.* **2012**, *124*, 9519–9522; *Angew. Chem. Int. Ed.* **2012**, *51*, 9385–9388.
- [16] CCDC 959663 (compound **6**) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
- [17] A 25.0 mmol scale 1,6-boration of **2a** with a 0.02 mol % catalyst loading was complete in 15 h, and provided **4a** in 92 % yield and 94 % ee after oxidation of **3a** (see the Supporting Information for full details).
- [18] For BF₃·OEt₂-promoted, *E*-selective allylboration of aldehydes with chiral secondary *E*-allylboronate esters, see Ref. [4e] and: a) F. Peng, D. G. Hall, *J. Am. Chem. Soc.* **2007**, *129*, 3070–3071; b) M. Chen, W. R. Roush, *Org. Lett.* **2010**, *12*, 2706–2709.
- [19] B. D. Roth, C. J. Blankley, A. W. Chucholowski, E. Ferguson, M. L. Hoefle, D. F. Ortwin, R. S. Newton, C. S. Sekerke, D. R. Sliskovic, M. Wilson, *J. Med. Chem.* **1991**, *34*, 357–366.
- [20] Reviews: a) B. D. Roth in *Progress in Medicinal Chemistry*, Vol. 40 (Eds.: F. D. King, A. W. Oxford, A. B. Reitz, S. L. Dax), **2002**, pp. 1–22; b) J. J. Li, D. S. Johnson, D. R. Sliskovic, B. D. Roth in *Contemporary Drug Synthesis*, Wiley, Weinheim, **2004**, pp. 113–124; c) Z. Casar, *Curr. Org. Chem.* **2010**, *14*, 816–845.

- [21] Selected recent syntheses of atorvastatin: a) Y. Kawato, M. Iwata, R. Yazaki, N. Kumagai, M. Shibasaki, *Tetrahedron* **2011**, 67, 6539–6546; b) L. Hu, F. Xiong, X. Chen, W. Chen, Q. He, F. Chen, *Tetrahedron: Asymmetry* **2013**, 24, 207–211; c) Y. Kawato, S. Chaudhary, N. Kumagai, M. Shibasaki, *Chem. Eur. J.* **2013**, 19, 3802–3806.
- [22] See the Supporting Information for details of the synthesis of **8**.
- [23] The 2*E*,4*Z*- $\alpha,\beta,\gamma,\delta$ -unsaturated ester **14** underwent 1,6-boration–oxidation to give *ent*-**4g** in only 42% *ee*, with the opposite absolute configuration to that depicted in Scheme 1.



- [24] D. A. Evans, J. A. Gauchet-Prunet, *J. Org. Chem.* **1993**, 58, 2446–2453.